Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC-Reference-Cited by-同舟云学术

Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

Published:2021-10 Issue:10 Volume:16 Page:1718-1732
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Herbst Roy S.,Garon Edward B.,Kim Dong-Wan,Cho Byoung Chul,Gervais Radj,Perez-Gracia Jose L.,Han Ji-Youn,Majem Margarita,Forster Martin D.,Monnet Isabelle,Novello Silvia,Gubens Matthew A.,Boyer Michael,Su Wu-Chou,Samkari Ayman,Jensen Erin H.,Kobie Julie,Piperdi Bilal,Baas Paul

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference25 articles.

1. PD-1 blockade in advanced NSCLC: a focus on pembrolizumab;Peters;Cancer Treat Rev,2018

2. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non–small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

3. Pembrolizumab versus chemotherapy for PD-L1-positive non–small-cell lung cancer;Reck;N Engl J Med,2016

4. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study;Langer;Lancet Oncol,2016

5. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer;Gandhi;N Engl J Med,2018

Cited by 180 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Review of immunotherapy in non-small cell lung cancer: mechanisms, clinical applications, and future prospects;Asia-Pacific Journal of Oncology;2024-09-11

2. The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies;Future Oncology;2024-09-04

3. Functions of CAFs in microenvironment of non-small cell lung cancer: based on updated hallmarks of cancer;Oncologie;2024-09-02

4. 5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC;CLIN LUNG CANCER;2024

5. 5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC;Clinical Lung Cancer;2024-09